Mainstream

Oruka jumps as lead drug outperforms AbbVie’s Skyrizi in early-stage trial

Oruka jumps as lead drug outperforms AbbVie’s Skyrizi in early-stage trial

Post Contentorka, abbvRead More

You might also be interested in reading Global supply chains threatened by lack of Chinese rare earths.

September 17, 2025
In Mainstream